Literature DB >> 17508418

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level.

Marie-Armelle Denis1, Catherine Reenaers, Fernand Fontaine, Jacques Belaïche, Edouard Louis.   

Abstract

BACKGROUND: Patients with clinically active Crohn's disease (CD), defined by a Crohn's Disease Activity Index (CDAI)>150, may have normal C-reactive protein (CRP) serum levels. In such cases, it is difficult to know whether these patients have really active disease or rather functional symptoms. This distinction is important to decide the most appropriate treatment. The aim of our work was to assess intestinal and colonic lesions in such patients and to look for biological markers potentially associated with endoscopic activity of the disease.
METHODS: We included 28 consecutive CD patients with CDAI>150 and a normal CRP level. These patients underwent a full colonoscopy with Crohn's Disease Endoscopy Index of Severity (CDEIS) calculation, fecal calprotectin, blood fibrinogen, acid alpha-1 glycoprotein, and erythrocyte sedimentation rate measurement. The Harvey-Bradshaw score was also calculated. Serum IL1 beta, IL6, IL8, sIL2R, and sTNFR2 were measured.
RESULTS: The median CDAI was 181 (151-485). Almost all (92.9%) these patients had endoscopic lesions, but the majority had only mild lesions (CDEIS<or=6). No correlation was found between CDEIS and any of the clinical or biological markers. However, all the patients with significant endoscopic lesions (defined by a CDEIS>6) had previous surgical intestinal resection and lesions involving the anastomosis.
CONCLUSIONS: Patients with elevated CDAI and normal CRP have only mild mucosal lesions of CD. Most significant lesions may be observed at the anastomosis and proximal to it in previously operated patients. None of the biological markers tested was associated with these endoscopic lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508418     DOI: 10.1002/ibd.20178

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  36 in total

1.  Utility of faecal calprotectin analysis in adult inflammatory bowel disease.

Authors:  Lyn A Smith; Daniel R Gaya
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

2.  Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD.

Authors:  Ellen J Scherl; Ernest G Seidman; Douglas C Wolf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-12

3.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

4.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

5.  Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale.

Authors:  Bijal Surti; Brennan Spiegel; Andrew Ippoliti; Eric A Vasiliauskas; Peter Simpson; David Q Shih; Stephan R Targan; Dermot P B McGovern; Gil Y Melmed
Journal:  Dig Dis Sci       Date:  2012-12-19       Impact factor: 3.199

6.  C-reactive protein and disease activity in children with Crohn's disease.

Authors:  Samantha Tilakaratne; Daniel A Lemberg; Steven T Leach; Andrew S Day
Journal:  Dig Dis Sci       Date:  2010-01       Impact factor: 3.199

7.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

8.  Assessment of activity of Crohn's disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score.

Authors:  L Macarini; L P Stoppino; A Centola; S Muscarella; F Fortunato; F Coppolino; N Della Valle; V Ierardi; P Milillo; R Vinci
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

9.  Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis.

Authors:  Didia Bismara Cury; Sender Jankiel Mizsputen; Clara Versolato; Luciana Odashiro Miiji; Edson Pereira; Maria Aparecida Delboni; Nestor Schor; Alan C Moss
Journal:  Cell Immunol       Date:  2013-04-23       Impact factor: 4.868

Review 10.  Endoscopic scoring indices for evaluation of disease activity in Crohn's disease.

Authors:  Reena Khanna; Sigrid A Nelson; Brian G Feagan; Geert D'Haens; William J Sandborn; G Y Zou; John K MacDonald; Claire E Parker; Vipul Jairath; Barrett G Levesque
Journal:  Cochrane Database Syst Rev       Date:  2016-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.